- Capital Cube•5 hours ago
Click here to see latest analysis ETF’s with exposure to Hikma Pharmaceuticals Plc Here are 5 ETF’s with the largest exposure to HIK-GB. Comparing the performance and risk of Hikma Pharmaceuticals Plc with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker […]
- Capital Cube•7 days ago
Hikma Pharmaceuticals Plc relative valuation is now UNDERVALUED. It was previously rated NEUTRAL, and has a fundamental analysis score of 72.Our analysis is based on comparing Hikma Pharmaceuticals Plc with the following peers – Dechra Pharmaceuticals PLC, BTG plc, GlaxoSmithKline plc, GW Pharmaceuticals PLC, AstraZeneca PLC, Summit Therapeutics plc, Sinclair Pharma plc and Vectura Group […] (Read more...) The post Hikma Pharmaceuticals Plc : Undervalued relative to peers, but don’t ignore the other factors appeared first on CapitalCube.
|Bid||2,360.00 x 10900|
|Ask||2,647.00 x 20000|
|52wk Range||1,575.00 - 2,652.00|
|Day's Range||2,588.00 - 2,642.00|
|Avg Vol (3m)||628,873|
As of 12:09 PM EDT. Market closed.